Skip to main content

EDITORIAL article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1500864
This article is part of the Research Topic Immunobiology and Immunotherapeutics in Myelodysplastic Syndrome and Acute Myeloid Leukemia View all 6 articles

Editorial: Immunobiology and Immunotherapeutics in Myelodysplastic Neoplasms and

Provisionally accepted
  • 1 UMass Chan Medical School, Worcester, United States
  • 2 Haematology and Stem Cell Transplant Center, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
  • 3 Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
  • 4 Institute of Translational Pharmacology, National Research Council of Italy, L'Aquila, Italy

The final, formatted version of the article will be published soon.

    Keywords: Myelodyslastic syndromes, Acute Myeloid Leukemia, Immunotherapy, Leukemia, Myeloid neoplasia

    Received: 24 Sep 2024; Accepted: 01 Oct 2024.

    Copyright: © 2024 Patel, Isidori, Cerchione and Aureli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Shyam A. Patel, UMass Chan Medical School, Worcester, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.